Table 1.
Baseline characteristics
| Characteristic, n (%) | N = 113 (Selected set) | N = 104 (Analysis set) | ||
|---|---|---|---|---|
| Case n = 23 | Control n = 90 | Case n = 21 | Control n = 83 | |
| Gender | ||||
| Male | 18 (78) | 70 (78) | 17 (81) | 66 (80) |
| Female | 5 (22) | 20 (22) | 4 (19) | 17(20) |
| Age | ||||
| <65 years | 13 (57) | 47 (52) | 11(52) | 43 (52) |
| ≥65 years | 10 (43) | 43 (48) | 10 (48) | 40 (48) |
| Histology | ||||
| Adenocarcinoma | 20 (87) | 89 (99) | 18 (86) | 83 (100) |
| Other | 3 (13) | 1 (1) | 3 (14) | 0 (0) |
| ECOG performance status at baseline | ||||
| 0/1 | 22 (96) | 87 (97) | 20 (95) | 80 (96) |
| 2 | 1 (4) | 3 (3) | 1 (5) | 3 (4) |
| Disease stage | ||||
| IIIB/IV | 15(65) | 65 (72) | 15 (71) | 61 (73) |
| Post‐operative recurrence | 4 (17) | 17 (19) | 2 (10) | 14 (17) |
| Other | 4 (17) | 8 (9) | 4 (19) | 8 (10) |
| Previous drug therapy (anticoagulant, aspirin, antiplatelet) | ||||
| No | 9 (39) | 65 (72) | 8 (38) | 60 (72) |
| Yes | 14 (60) | 25 (27) | 13 (62) | 23 (28) |
| Previous thoracic radiotherapy | ||||
| No | 15 (65) | 80 (88) | 14 (67) | 74 (89) |
| Yes | 8 (34) | 10 (11) | 7 (33) | 9 (11) |
| Concomitant thoracic radiotherapy | ||||
| No | 20 (87) | 88 (98) | 18 (86) | 81 (98) |
| Yes | 3 (13) | 2 (2) | 3 (14) | 2 (2) |
| Treatment line | ||||
| First‐line therapy | 13 (57) | 52 (58) | 13 (62) | 50 (60) |
| Second‐line or later line therapy | 10 (43) | 38 (42) | 8 (38) | 33 (40) |
ECOG, Eastern Cooperative Oncology Group.